Curcumin vs Low-dose naltrexone
Both get reached for in chronic pain and inflammation: an over-the-counter botanical that barely absorbs, and a compounded prescription whose best trial came back null.
Curcumin
Turmeric extract
Decent RCT/meta-analysis support for osteoarthritis pain — but curcumin is barely absorbed (hence piperine/formulations) and a textbook PAINS compound that lights up assays deceptively.
Full Curcumin evidence reviewLow-dose naltrexone
LDN, naltrexone 1.5–4.5 mg
Cheap, low-risk and mechanistically interesting via TLR4 — but the largest, best-designed fibromyalgia trial was null and Cochrane calls the Crohn's evidence insufficient.
Full Low-dose naltrexone evidence reviewSide by side
| Curcumin | Low-dose naltrexone | |
|---|---|---|
| Marketed for | Anti-inflammatory, joint pain | Fibromyalgia, chronic pain, autoimmune disease, ME/CFS, long COVID |
| Evidence grade | Clinical data | Clinical data |
| Family | mTOR & other | Immune & inflammation |
| Key human source | Joint-pain meta-analysis, J Med Food 2016 | FINAL trial, Lancet Rheumatol 2024 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Curcumin has the better outcome data, and it is narrow. A meta-analysis of randomised trials found turmeric and curcumin extracts reduced arthritis symptoms, particularly knee osteoarthritis pain, comparably to NSAIDs, though the trials were short and small — and two caveats sit on top of it: plain curcumin is barely absorbed, which is why products bolt on piperine or phospholipid delivery, and medicinal chemists formally classify it as a PAINS compound that produces false positives across a huge range of assays. Low-dose naltrexone has the more interesting mechanism, TLR4 antagonism on microglia, supported by the fact that the opioid-inactive (+)-isomer does the same thing, but the trial record does not follow the mechanism: two small Stanford crossover studies in fibromyalgia were encouraging, and the larger, independently funded FINAL trial in 99 women found a between-group pain difference of 0.34 points on an 11-point scale (p = 0.27), well below any clinically meaningful threshold, while Cochrane calls the Crohn's evidence insufficient. One practical difference outweighs much of the above: naltrexone blocks opioid analgesia at any dose, so anyone taking it has to tell every clinician, dentist and surgeon, and plan around elective surgery.
Curcumin fits if
Curcumin is a reasonable low-risk try for joint pain specifically, using a formulation built for absorption and watching for the piperine-driven drug interactions, rather than expecting the cure-all its mechanistic literature implies.
Low-dose naltrexone fits if
Low-dose naltrexone is a clinician conversation rather than a purchase — no approved product exists at 1.5 to 4.5 mg, so every prescription is compounded — and it is worth having only with the null FINAL result and the opioid-blockade constraint already understood.